MediWound Ltd. (MDWD)
19.10
0.81 (4.43%)
At close: Jan 14, 2025, 3:59 PM
19.03
-0.36%
After-hours Jan 14, 2025, 05:23 PM EST
undefined% (undefined)
| Bid | 18.75 |
| Market Cap | 206.02M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.91 |
| PE Ratio (ttm) | -6.56 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 19.3 |
| Volume | 113,974 |
| Avg. Volume (20D) | 52,531 |
| Open | 18.42 |
| Previous Close | 18.29 |
| Day's Range | 17.79 - 19.18 |
| 52-Week Range | 11.04 - 24.00 |
| Beta | undefined |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 20, 2014
Employees 100
Stock Exchange NASDAQ
Ticker Symbol MDWD
Website https://www.mediwound.com
Analyst Forecast
According to 1 analyst ratings, the average rating for MDWD stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 30.89% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
MediWound Ltd. is scheduled to release its earnings on Mar 20, 2025,
before market opens.
Analysts project revenue of $5.79M, reflecting a 8.47% YoY growth and earnings per share of -0.64, making a 236.84% increase YoY.
Analysts project revenue of $5.79M, reflecting a 8.47% YoY growth and earnings per share of -0.64, making a 236.84% increase YoY.
